Status:
COMPLETED
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
Lead Sponsor:
MedImmune LLC
Conditions:
Esophagitis
Pneumonitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable...
Eligibility Criteria
Inclusion
- You may be eligible for this study if you are 18 years of age or older and:
- Have UnResectable Stage IIIA or IIIB Non Small Cell Lung Cancer
- Have never had prior chemotherapy with Paclitaxel or Carboplatin
- Have never had prior thoracic radiation therapy (XRT)
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00081315
Start Date
November 1 2003
End Date
August 1 2006
Last Update
August 21 2007
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars Sanai
Los Angeles, California, United States, 90048
2
Radiation Oncology Center
Sacramento, California, United States, 95816
3
The Center for Cancer Care
Torrington, Connecticut, United States, 06790
4
Florida Wellcare Alliance
Inverness, Florida, United States, 34452